These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38743695)

  • 1. Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers.
    Schejter-Margalit T; Binyamin NB; Thaler A; Maidan I; Cedarbaum JM; Orr-Urtreger A; Gana Weisz M; Goldstein O; Giladi N; Mirelman A; Kizony R
    Eur J Neurol; 2024 Aug; 31(8):e16327. PubMed ID: 38743695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
    Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
    JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
    Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
    J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.
    Pachi I; Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Stamelou M; Trapali XG; Papageorgiou SG; Stefanis L
    Parkinsonism Relat Disord; 2021 Oct; 91():1-8. PubMed ID: 34425330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative digital clock drawing test as a sensitive tool to detect subtle cognitive impairments in early stage Parkinson's disease.
    Schejter-Margalit T; Kizony R; Shirvan J; Cedarbaum JM; Bregman N; Thaler A; Giladi N; Mirelman A
    Parkinsonism Relat Disord; 2021 Sep; 90():84-89. PubMed ID: 34416663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of p.G2019S Mutation in the
    Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
    J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
    Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.
    Gan-Or Z; Bar-Shira A; Mirelman A; Gurevich T; Kedmi M; Giladi N; Orr-Urtreger A
    Neurogenetics; 2010 Feb; 11(1):121-5. PubMed ID: 19458969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.
    Alcalay RN; Caccappolo E; Mejia-Santana H; Tang M-; Rosado L; Orbe Reilly M; Ruiz D; Ross B; Verbitsky M; Kisselev S; Louis E; Comella C; Colcher A; Jennings D; Nance M; Bressman S; Scott WK; Tanner C; Mickel S; Andrews H; Waters C; Fahn S; Cote L; Frucht S; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Payami H; Molho E; Factor S; Ottman R; Clark LN; Marder K
    Neurology; 2012 May; 78(18):1434-40. PubMed ID: 22442429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Ortega RA; Bressman SB; Raymond D; Ozelius LJ; Katsnelson V; Leaver K; Swan MC; Shanker V; Miravite J; Wang C; Bennett SAL; Saunders-Pullman R
    Mov Disord; 2022 Nov; 37(11):2217-2225. PubMed ID: 36054306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
    Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.